daunorubicin has been researched along with Cardiotoxicity in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 18 (60.00) | 24.3611 |
| 2020's | 12 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Austin, CA; Bavlovič Piskáčková, H; Jirkovská, A; Jirkovský, E; Karabanovich, G; Korábečný, J; Kubeš, J; Kučera, T; Melnikova, I; Nováková, L; Roh, J; Šimůnek, T; Skalická, V; Škoda, J; Štěrba, M | 1 |
| Adamcová, M; Holečková, M; Jirkovský, E; Kollárová-Brázdová, P; Kubeš, J; Lenčová-Popelová, O; Mazurová, Y; Palička, V; Pokorná, Z; Šimůnek, T; Štěrba, M | 1 |
| Blanco, JG; Cejas, RB; Fontecha, JE; Tamaño-Blanco, M | 1 |
| Bai, R; Chang, X; Li, L; Li, Y; Lin, R; Liu, N; Liu, X; Peng, X; Ruan, Y; Tang, R; Wang, X; Wen, S | 1 |
| Bucki, A; Jamrozik, M; Koczurkiewicz-Adamczyk, P; Kołaczkowski, M; Pękala, E; Piska, K; Sapa, M; Władyka, B | 1 |
| Chang, JJ; Gui, LX; He, RL; Huang, ZH; Jiang, JF; Jiao, HX; Lin, JJ; Lin, MJ; Wang, RX; Wu, ZJ; Xu, LX; Yi, GC; Zheng, B | 1 |
| Fortin, MC; Grammatopoulos, TN; LaCroix, AS; Manca, D; Tan, L; Wang, Q | 1 |
| Adamcova, M; Brazdova, P; Hlavackova, M; Holzerova, K; Jansova, H; Jirkovska, A; Jirkovsky, E; Kolar, F; Kubes, J; Lencova-Popelova, O; Mazurova, Y; Pokorna, Z; Simunek, T; Sotakova-Kasparova, D; Sterba, M; Vostatkova, L | 1 |
| Akhter, N; Altman, JK; Canaani, J; Cascino, GJ; Foran, JM; Furiasse, N; Ky, B; Litzow, MR; Luger, S; Rademaker, A; Rigolin, V; Tallman, MS; Voss, WB | 1 |
| Arao, Y; Fujimoto, K; Fukaya, K; Furusawa, K; Haga, T; Hiraiwa, H; Kano, N; Kato, H; Kondo, T; Kuwayama, T; Morimoto, R; Murohara, T; Mutsuga, M; Oishi, H; Okumura, T; Sawamura, A; Shimizu, S; Sugiura, Y; Usui, A; Watanabe, N; Yamaguchi, S; Yokoi, T | 1 |
| Chen, YY; Fu, LX; Gan, RZ; Li, L; Liang, G; Lv, MX; Zhang, XX; Zhou, H; Zhou, JL; Zhu, HQ | 1 |
| Das, KC; Kundumani-Sridharan, V; Muniyappa, H; Subramani, J | 1 |
| Andarsini, MR; Cahyadi, A; Hidayat, T; Larasati, MCS; Ontoseno, T; Rahman, MA; Samosir, SM; Ugrasena, IDG; Utamayasa, IKA | 1 |
| Adamcová, M; Holečková, M; Jirkovská, A; Karabanovich, G; Kocúrová-Lengvarská, J; Kollárová-Brázdová, P; Kubeš, J; Lenčová-Popelová, O; Mazurová, Y; Roh, J; Šimůnek, T; Štěrba, M; Štěrbová-Kovaříková, P; Váňová, N | 1 |
| Hammond, HK; Ichikawa, Y; Manso, AM; McKirnan, MD; Patel, HH; Ross, RS; Roth, DM; Zemljic-Harpf, AE; Zhang, Z | 1 |
| Bures, J; Jansova, H; Jirkovska, A; Karabanovich, G; Kovarikova, P; Roh, J; Sestak, V; Simunek, T; Sterba, M | 1 |
| Babaoğlu, K; Başar, EZ; Çetin, S; Çorapçıoğlu, F; Deveci, M | 1 |
| Abdelhamid, G; Alammari, AH; Althurwi, HN; Dawood, D; El-Kadi, AOS; El-Sherbeni, AA; Elshenawy, OH; Maayah, ZH; McGinn, E | 1 |
| Chang, VY; Wang, JJ | 1 |
| Agrawal, V; Bali Singh, T; Gupta, V; Kumar Singh, S | 1 |
| Arshad, N; Nosheen, B; Nowsherwan, J; Perveen, F; Qureshi, R; Rafique, H; Sultan, A | 1 |
| Alonzo, T; Aplenc, R; Gamis, A; Gerbing, RB; Getz, KD; Ky, B; Leahy, AB; Leger, KJ; Sack, L; Sung, L; Woods, WG | 1 |
| Chen, M; Haddad, AS; Henderson, PT; Jonas, BA; Lam, KS; Li, Y; Lin, TY; Liu, R; Pan, CX; Xiao, K; Xiao, W; Zhang, H | 1 |
| Fang, QJ; He, RL; Lian, JB; Wu, ZJ; Yu, J | 1 |
| Kik, K; Lukawska, M; Oszczapowicz, I; Strek, M; Studzian, K; Szmigiero, L | 1 |
| Adamcova, M; Gersl, V; Jirkovsky, E; Lencova-Popelova, O; Mazurova, Y; Palicka, V; Simko, F; Sterba, M | 1 |
| Dorokhina, EI; Gitis, MK; Kravchenko, SK; Kulikov, SM; Magomedova, AU; Shevelev, AA; Vedernikov, AV; Vorobyev, AI | 1 |
| Adamcová, M; Chládek, J; Geršl, V; Hroch, M; Jansová, H; Jirkovská-Vávrová, A; Jirkovský, E; Lenčová-Popelová, O; Mazurová, Y; Pokorná, Z; Šimůnek, T; Štěrba, M; Vostatková-Tichotová, L | 1 |
| Adamcová, M; Bureš, J; Hroch, M; Jansová, H; Jirkovská-Vávrová, A; Jirkovský, E; Kovaříková, P; Lenčová-Popelová, O; Mazurová, Y; Pokorná, Z; Reimerová, P; Šimůnek, T; Štěrba, M; Vostatková, L | 1 |
| Hu, M; Jiang, H; Xia, M | 1 |
2 review(s) available for daunorubicin and Cardiotoxicity
| Article | Year |
|---|---|
The Role of Mitochondrial Quality Control in Anthracycline-Induced Cardiotoxicity: From Bench to Bedside.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Calcium; Cardiotoxicity; Daunorubicin; Doxorubicin; Epirubicin; Humans; Idarubicin; Mitochondria; Mitochondrial Proteins; Myocytes, Cardiac; Reactive Oxygen Species | 2022 |
Pharmacogenetics of Chemotherapy-Induced Cardiotoxicity.
Topics: Animals; Antineoplastic Agents; Cardiotoxicity; Daunorubicin; Doxorubicin; Genetic Testing; Humans; Mice; Pharmacogenetics; Polymorphism, Single Nucleotide; Receptors, Retinoic Acid; Retinoic Acid Receptor gamma | 2018 |
4 trial(s) available for daunorubicin and Cardiotoxicity
| Article | Year |
|---|---|
Two-dimensional speckle-tracking strain detects subclinical cardiotoxicity in older patients treated for acute myeloid leukemia.
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Cardiotoxicity; Clofarabine; Cytarabine; Daunorubicin; Echocardiography; Female; Follow-Up Studies; Heart Ventricles; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Retrospective Studies; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left | 2019 |
Role of ACE inhibitors in anthracycline-induced cardiotoxicity: A randomized, double-blind, placebo-controlled trial.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anthracyclines; Antibiotics, Antineoplastic; Cardiotoxicity; Child; Daunorubicin; Double-Blind Method; Doxorubicin; Enalapril; Female; Heart Failure; Humans; Lymphoma; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2018 |
Occurrence of Treatment-Related Cardiotoxicity and Its Impact on Outcomes Among Children Treated in the AAML0531 Clinical Trial: A Report From the Children's Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicity; Child; Child, Preschool; Daunorubicin; Disease-Free Survival; Echocardiography; Humans; Incidence; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Mitoxantrone; Proportional Hazards Models; Risk Factors; Survival Rate; Treatment Outcome | 2019 |
[Late cardiotoxicity of high-dose chemotherapy according to the modified NHL-BFM-90 program in adult patients with diffuse large B-cell lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cardiotoxicity; Daunorubicin; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Incidence; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Prognosis; Retrospective Studies; Russia; Survival Rate; Time Factors; Vincristine | 2015 |
24 other study(ies) available for daunorubicin and Cardiotoxicity
| Article | Year |
|---|---|
Structure-Activity Relationship Study of Dexrazoxane Analogues Reveals ICRF-193 as the Most Potent Bisdioxopiperazine against Anthracycline Toxicity to Cardiomyocytes Due to Its Strong Topoisomerase IIβ Interactions.
Topics: Animals; Animals, Newborn; Cardiotonic Agents; Cardiotoxicity; Cell Line, Tumor; Cell Proliferation; Daunorubicin; Diketopiperazines; DNA Topoisomerases, Type II; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Structure; Myocytes, Cardiac; Piperazines; Protein Binding; Rats, Wistar; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2021 |
Primary prevention of chronic anthracycline cardiotoxicity with ACE inhibitor is temporarily effective in rabbits, but benefits wane in post-treatment follow-up.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antibiotics, Antineoplastic; Cardiotoxicity; Daunorubicin; Heart Diseases; Heart Failure; Male; Perindopril; Rabbits; Troponin T | 2022 |
Impact of DYRK1A Expression on TNNT2 Splicing and Daunorubicin Toxicity in Human iPSC-Derived Cardiomyocytes.
Topics: Adult; Cardiotoxicity; Daunorubicin; Dyrk Kinases; Humans; Induced Pluripotent Stem Cells; Myocytes, Cardiac; Phosphoproteins; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Serine-Arginine Splicing Factors; Troponin T | 2022 |
In Silico and In Vitro Assessment of Carbonyl Reductase 1 Inhibition Using ASP9521-A Potent Aldo-Keto Reductase 1C3 Inhibitor with the Potential to Support Anticancer Therapy Using Anthracycline Antibiotics.
Topics: Animals; Anthracyclines; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antineoplastic Agents; Carbonyl Reductase (NADPH); Cardiotoxicity; Daunorubicin; Humans; Molecular Docking Simulation; Rats | 2023 |
TRPC6 promotes daunorubicin-induced mitochondrial fission and cell death in rat cardiomyocytes with the involvement of ERK1/2-DRP1 activation.
Topics: Animals; Apoptosis; Cardiotoxicity; Cell Death; Daunorubicin; Dynamins; MAP Kinase Signaling System; Mitochondrial Dynamics; Myocytes, Cardiac; Rats; TRPC Cation Channels; TRPC6 Cation Channel | 2023 |
Lower cardiotoxicity of CPX-351 relative to daunorubicin plus cytarabine free-drug combination in hiPSC-derived cardiomyocytes in vitro.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Cardiotoxicity; Cytarabine; Daunorubicin; Drug Combinations; Humans; Induced Pluripotent Stem Cells; Liposomes; Myocytes, Cardiac; Topoisomerase II Inhibitors | 2023 |
Topics: Animals; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cardiotoxicity; Daunorubicin; Dose-Response Relationship, Drug; Male; Myocytes, Cardiac; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Rabbits; Rats; Rats, Wistar | 2019 |
Pathological changes of the myocardium in reworsening of anthracycline-induced cardiomyopathy after explant of a left ventricular assist device.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathies; Cardiotoxicity; Daunorubicin; Device Removal; Disease Progression; Female; Fibrosis; Heart-Assist Devices; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Myocardium; Time Factors; Ventricular Function, Left | 2020 |
The epigallocatechin gallate derivative Y6 reduces the cardiotoxicity and enhances the efficacy of daunorubicin against human hepatocellular carcinoma by inhibiting carbonyl reductase 1 expression.
Topics: Alcohol Oxidoreductases; Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Carcinoma, Hepatocellular; Cardiotoxicity; Catechin; Cell Proliferation; Daunorubicin; Drug Synergism; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Heart Rate; Hep G2 Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2020 |
Thioredoxin Decreases Anthracycline Cardiotoxicity, But Sensitizes Cancer Cell Apoptosis.
Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Cardiotoxicity; Daunorubicin; HCT116 Cells; Humans; MCF-7 Cells; Myocytes, Cardiac; Neoplasms; Poly(ADP-ribose) Polymerases; Rats; Thioredoxins; Tumor Suppressor Protein p53; U937 Cells | 2021 |
Risk Factors of Daunorubicine Induced Early Cardiotoxicity in Childhood Acute Lymphoblastic Leukemia: A Retrospective Study.
Topics: Adolescent; Antibiotics, Antineoplastic; Cardiotoxicity; Child; Child, Preschool; Daunorubicin; Female; Follow-Up Studies; Humans; Indonesia; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Retrospective Studies; Risk Factors; ROC Curve | 2021 |
Prodrug of ICRF-193 provides promising protective effects against chronic anthracycline cardiotoxicity in a rabbit model in vivo.
Topics: Animals; Cardiomyopathies; Cardiotoxicity; Chronic Disease; Daunorubicin; Diketopiperazines; Disease Models, Animal; DNA Damage; Fibrosis; HL-60 Cells; Humans; Male; Myocytes, Cardiac; Prodrugs; Rabbits; Topoisomerase II Inhibitors; Tumor Suppressor Protein p53; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2021 |
Modulation of caveolins, integrins and plasma membrane repair proteins in anthracycline-induced heart failure in rabbits.
Topics: Animals; Anthracyclines; Blotting, Western; Cardiotoxicity; Caveolins; Cholesterol; Daunorubicin; Echocardiography; Heart Failure; Immunohistochemistry; Integrins; Microscopy, Electron; Myocardium; Rabbits | 2017 |
Investigation of novel dexrazoxane analogue JR-311 shows significant cardioprotective effects through topoisomerase IIbeta but not its iron chelating metabolite.
Topics: Animals; Animals, Newborn; Anthracyclines; Cardiotonic Agents; Cardiotoxicity; Cell Proliferation; Cells, Cultured; Daunorubicin; Dexrazoxane; Diketopiperazines; DNA Topoisomerases, Type II; Iron; Iron Chelating Agents; Myocytes, Cardiac; Rats; Rats, Wistar; Structure-Activity Relationship | 2017 |
Subclinical anthracycline-induced cardiotoxicity in long-term follow-up of asymptomatic childhood cancer survivors: Assessment by speckle tracking echocardiography.
Topics: Adolescent; Adult; Anthracyclines; Antibiotics, Antineoplastic; Cancer Survivors; Cardiotoxicity; Child; Child, Preschool; Daunorubicin; Doxorubicin; Echocardiography; Female; Follow-Up Studies; Heart Ventricles; Humans; Male; Neoplasms; Prospective Studies; Ventricular Dysfunction, Left; Young Adult | 2018 |
The Role of Soluble Epoxide Hydrolase Enzyme on Daunorubicin-Mediated Cardiotoxicity.
Topics: Animals; Antibiotics, Antineoplastic; Cardiomegaly; Cardiotoxicity; Cells, Cultured; Cytochrome P-450 Enzyme System; Daunorubicin; Disease Models, Animal; Enzyme Inhibitors; Epoxide Hydrolases; Fibrosis; Humans; Hydroxyeicosatetraenoic Acids; Male; Myocytes, Cardiac; NF-kappa B p50 Subunit; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Rats, Sprague-Dawley; Signal Transduction | 2018 |
Electrochemical, spectroscopic and theoretical monitoring of anthracyclines' interactions with DNA and ascorbic acid by adopting two routes: Cancer cell line studies.
Topics: Antibiotics, Antineoplastic; Antioxidants; Ascorbic Acid; Cardiotoxicity; Cell Line, Tumor; Cell Proliferation; Daunorubicin; DNA; Doxorubicin; Drug Interactions; Epirubicin; Humans; Hydrogen-Ion Concentration; Molecular Docking Simulation; Neoplasms | 2018 |
Nanomicelle formulation modifies the pharmacokinetic profiles and cardiac toxicity of daunorubicin.
Topics: Animals; Antibiotics, Antineoplastic; Cardiotoxicity; Caspases; Chemistry, Pharmaceutical; Daunorubicin; Dendrimers; Drug Delivery Systems; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred BALB C; Micelles; Myocardium; Nanomedicine; Neoplastic Stem Cells; Rats; Rats, Sprague-Dawley | 2014 |
[Sodium ferulate protects against daunorubicin-induced cardiotoxicity in juvenile rats].
Topics: Animals; Blood Pressure; Cardiotoxicity; Coumaric Acids; Daunorubicin; Heart; Heart Rate; Isoproterenol; Male; Myocardium; Protective Agents; Rats; Rats, Sprague-Dawley; Troponin I | 2015 |
Subcellular localization of anthracyclines in cultured rat cardiomyoblasts as possible predictors of cardiotoxicity.
Topics: Animals; Anthracyclines; Cardiotoxicity; Cell Cycle; Cell Nucleus; Daunorubicin; DNA-Binding Proteins; Doxorubicin; Myoblasts, Cardiac; Rats; Structure-Activity Relationship | 2015 |
Experimental determination of diagnostic window of cardiac troponins in the development of chronic anthracycline cardiotoxicity and estimation of its predictive value.
Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Biomarkers; Cardiomyopathies; Cardiotoxicity; Daunorubicin; Disease Models, Animal; Echocardiography; Heart; Male; Predictive Value of Tests; Rabbits; Regression Analysis; Systole; Troponin I; Troponin T | 2015 |
Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: Comparison with dexrazoxane.
Topics: Animals; Antibiotics, Antineoplastic; Cardiotonic Agents; Cardiotoxicity; Daunorubicin; Dexrazoxane; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Administration Schedule; Infusions, Intravenous; Male; Myocardium; Myocytes, Cardiac; Nitrates; Rabbits; Sodium Nitrite | 2016 |
Are cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings?
Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Cardiotonic Agents; Cardiotoxicity; Cell Line, Tumor; Cell Proliferation; Chronic Disease; Daunorubicin; Doxorubicin; Heart Diseases; Heart Failure; Lipid Peroxidation; Molsidomine; Nitric Oxide Donors; Oxidative Stress; Rabbits; Reactive Oxygen Species; Ventricular Remodeling | 2016 |
[NT-pro-BNP in the evaluation of daunorubicin-indued cardiotoxicity in acute childhood leukemia].
Topics: Anthracyclines; Cardiotoxicity; Daunorubicin; Humans; Idarubicin; Leukemia | 2010 |